Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR | MarketsandMarkets™
DELRAY BEACH, Fla., Aug 5, 2025 /PRNewswire/ -- The global Liquid Biopsy Market, valued at US$3.65 billion in 2024 stood at US$4.03 billion in 2025 and is projected to advance at a resilient CAGR of 11.8% from 2025 to 2030, culminating in a forecasted valuation of US$7.05 billion by the end of the period. The increasing global cancer incidence and the growing emphasis on early and precise disease detection primarily drive this market expansion. Liquid biopsy techniques enable real-time tumor monitoring and facilitate the tracking of resistance development to specific therapies, thereby providing crucial insights for physicians utilizing targeted cancer treatments. Furthermore, these tests are gaining traction in non-invasive prenatal testing and transplantation, broadening their clinical utility.
Additionally, technological advancements such as next-generation sequencing (NGS) and improved biomarker detection methods are enhancing the sensitivity and reliability of liquid biopsy tests. Furthermore, rising investments from both public and private sectors in precision medicine, coupled with a growing demand for early and non-invasive diagnostic solutions, are further propelling the adoption of liquid biopsy across various healthcare settings.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350
Browse in-depth TOC on "Liquid Biopsy Market"
486 - Tables
60 - Figures
393 - Pages
By technology, the liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using NGS segment accounted for the largest share of the market. The large share of this segment is attributed to NGS's ability to analyze multiple genetic alterations simultaneously, offering comprehensive molecular profiling with high accuracy. Its high-throughput capacity, flexibility, and suitability for detecting complex genomic changes make it ideal for clinical applications such as therapy selection and monitoring. The integration of NGS into personalized medicine strategies and its growing use in routine diagnostics further contribute to market growth.
By application, the liquid biopsy market is segmented into cancer and non-cancer applications. In 2024, the cancer applications segment accounted for the largest share of the market. This dominance is primarily driven by the rising global incidence of cancer and the increasing volume of research focused on utilizing liquid biopsy in oncology. The segment's growth is further supported by liquid biopsy's ability to monitor tumor progression in real time, detect minimal residual disease, and overcome limitations associated with traditional tissue biopsies.
By geography, the liquid biopsy market is segmented into five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of the market. The large share of this market is attributed to the region's well-established healthcare infrastructure, which includes advanced diagnostic capabilities, specialized cancer care centers, and a highly trained medical workforce. These factors collectively support the widespread adoption of liquid biopsy technologies and their integration into routine clinical practice, ensuring broader patient access across diverse healthcare settings.
Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350
The leading players operating in this market are Natera, Inc. (US), QIAGEN (Netherlands), Guardant Health (US), Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), GRAIL, Inc. (US), Bio-Rad Laboratories, Inc. (US), Exact Sciences Corporation (US), and Sysmex Corporation (Japan).
Natera, Inc. (US):
Natera, Inc. focuses heavily on R&D capabilities to enhance its portfolio of cell-free DNA-based tests to improve clinical decision-making across oncology, transplant, and reproductive health. Its investments in R&D and capital allocation strategies help fuel its future growth and ability to remain competitive. The company's strategies, including collaborations and acquisitions, aim to solidify its liquid biopsy market position further.
Guardant Health (US)
Guardant Health holds a significant share in the liquid biopsy market, supported by its broad distribution network spanning the Americas, Europe, the Middle East & Africa, and Asia Pacific. The company maintains a strong market presence by offering innovative, high-quality products across the entire value chain. Guardant Health emphasizes research and development and pursues organic growth strategies to reinforce its market position. For instance, in June 2025, the company's Shield multi-cancer detection (MCD) test received Breakthrough Device designation from the US FDA. This blood-based test utilizes methylation analysis to detect various cancers, including bladder, colorectal, lung, and pancreatic, in individuals aged 45 and older at average risk.
For more information, Inquire Now!
Related Reports:
Top 10 Medical Device Technologies Market
Get access to the latest updates on Liquid Biopsy Companies and Liquid Biopsy Market Size
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
Share this article